BR112022002122A2 - Composição de mascaramento de sabor dispersível oralmente de hemibromidrato de vortioxetina, método para preparação da composição de mascaramento de sabor dispersível oralmente, e método para tratamento de um transtorno de depressão em um indivíduo - Google Patents

Composição de mascaramento de sabor dispersível oralmente de hemibromidrato de vortioxetina, método para preparação da composição de mascaramento de sabor dispersível oralmente, e método para tratamento de um transtorno de depressão em um indivíduo

Info

Publication number
BR112022002122A2
BR112022002122A2 BR112022002122A BR112022002122A BR112022002122A2 BR 112022002122 A2 BR112022002122 A2 BR 112022002122A2 BR 112022002122 A BR112022002122 A BR 112022002122A BR 112022002122 A BR112022002122 A BR 112022002122A BR 112022002122 A2 BR112022002122 A2 BR 112022002122A2
Authority
BR
Brazil
Prior art keywords
taste masking
masking composition
orally dispersible
vortioxetine
hemihydrobromide
Prior art date
Application number
BR112022002122A
Other languages
English (en)
Inventor
Changhu Chu
Fa Huang
Jinjin Yang
Qiang Jia
Ru Wang
Tianhua Ma
Yanyun Hu
Youbing Wei
Yunzhong Wang
Original Assignee
Seasons Biotechnology Taizhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74736746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112022002122(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seasons Biotechnology Taizhou Co Ltd filed Critical Seasons Biotechnology Taizhou Co Ltd
Publication of BR112022002122A2 publication Critical patent/BR112022002122A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

trata-se de um grânulo revestido, uma dispersão sólida, uma composição e uma preparação para mascaramento de sabor oral que melhoram o efeito de mascaramento de sabor do bromidrato de vortioxetina e melhoram a aderência e a adesão do paciente.
BR112022002122A 2019-09-04 2020-09-03 Composição de mascaramento de sabor dispersível oralmente de hemibromidrato de vortioxetina, método para preparação da composição de mascaramento de sabor dispersível oralmente, e método para tratamento de um transtorno de depressão em um indivíduo BR112022002122A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910571194 2019-09-04
PCT/CN2020/113341 WO2021043227A1 (zh) 2019-09-04 2020-09-03 用于口腔掩味的含氢溴酸沃替西汀的包衣颗粒、固体分散体和制剂

Publications (1)

Publication Number Publication Date
BR112022002122A2 true BR112022002122A2 (pt) 2022-04-19

Family

ID=74736746

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002122A BR112022002122A2 (pt) 2019-09-04 2020-09-03 Composição de mascaramento de sabor dispersível oralmente de hemibromidrato de vortioxetina, método para preparação da composição de mascaramento de sabor dispersível oralmente, e método para tratamento de um transtorno de depressão em um indivíduo

Country Status (11)

Country Link
US (1) US20220249466A1 (pt)
EP (1) EP4026539A4 (pt)
JP (3) JP2022540249A (pt)
KR (1) KR20220061952A (pt)
CN (3) CN114796222B (pt)
AU (1) AU2020343816A1 (pt)
BR (1) BR112022002122A2 (pt)
CA (1) CA3146024A1 (pt)
MX (1) MX2022002444A (pt)
WO (1) WO2021043227A1 (pt)
ZA (1) ZA202200542B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113520998A (zh) * 2021-07-26 2021-10-22 北京丰科睿泰医药科技有限公司 一种伏硫西汀口服滴剂及其制备方法
CN116650488A (zh) * 2022-06-27 2023-08-29 中国人民解放军军事科学院军事医学研究院 一种氢溴酸伏硫西汀树脂复合物及其制备方法和其应用
GB2622880A (en) * 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2821745B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
JP2006514968A (ja) * 2003-04-02 2006-05-18 プリヴァ−イストラジヴァンジェ・イ・ラズヴォイ・ディー・オー・オー 低減された苦味を有する製薬組成物
BR122020011920A2 (pt) 2006-06-16 2020-08-25 Lundbeck & Co As H composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
US20160200698A1 (en) * 2013-09-12 2016-07-14 Hangzhou Pushai Pharmaceutical Technology Co., Ltd Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage
US10414741B2 (en) * 2013-09-30 2019-09-17 Cadila Healthcare Limited Amorphous vortioxetine and salts thereof
CN103989650A (zh) * 2014-06-13 2014-08-20 李雪梅 一种口腔崩解药物组合物及其制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CN105030713A (zh) * 2015-06-27 2015-11-11 万特制药(海南)有限公司 一种沃替西汀缓释片及其制备方法
CN105111167A (zh) * 2015-08-06 2015-12-02 华南理工大学 一种沃替西汀半盐酸盐及其制备方法和药物组合物
CN107638425A (zh) * 2016-07-21 2018-01-30 常州爱诺新睿医药技术有限公司 一种新的含无定型沃替西汀氢溴酸盐的药用组合物及其制备方法
CN106491604A (zh) * 2015-09-07 2017-03-15 常州方楠医药技术有限公司 一种无定型沃替西汀或其盐与药用辅料的组合物及其制备方法
EP3184104B1 (en) * 2015-12-23 2018-09-12 Hexal AG Pharmaceutical composition of vortioxetine hydrobromide comprising vortioxetine hydrobromide in a polyethylene oxide matrix
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药（厦门）有限公司 一种沃替西汀口腔崩解片及其制备方法
KR102429646B1 (ko) * 2016-03-14 2022-08-04 산텐 세이야꾸 가부시키가이샤 메글루민 또는 그의 염을 포함하는 방부제
WO2018065348A1 (en) * 2016-10-05 2018-04-12 Hexal Ag Novel enteric-coated tablet comprising vortioxetine
CN108069925A (zh) * 2016-11-16 2018-05-25 浙江京新药业股份有限公司 沃替西汀氢溴酸盐无水晶型i及其制备方法和应用
CN108498459A (zh) * 2017-02-23 2018-09-07 北京阜康仁生物制药科技有限公司 一种包含氢溴酸沃替西汀的药物组合物及其制备方法
CN107412183A (zh) * 2017-04-17 2017-12-01 深圳市泛谷药业股份有限公司 一种氢溴酸沃替西汀片及其制备方法
CN109589314A (zh) * 2017-10-01 2019-04-09 万全万特制药（厦门）有限公司 含有氢溴酸沃替西汀口崩片的制备方法

Also Published As

Publication number Publication date
ZA202200542B (en) 2023-11-29
WO2021043227A1 (zh) 2021-03-11
MX2022002444A (es) 2022-03-22
CN114796222A (zh) 2022-07-29
CN114796222B (zh) 2024-03-29
CN112438979A (zh) 2021-03-05
US20220249466A1 (en) 2022-08-11
CN114931579A (zh) 2022-08-23
EP4026539A4 (en) 2023-07-19
AU2020343816A1 (en) 2022-02-24
KR20220061952A (ko) 2022-05-13
JP2023089096A (ja) 2023-06-27
CA3146024A1 (en) 2021-03-11
CN112438979B (zh) 2022-05-27
EP4026539A1 (en) 2022-07-13
JP2022540249A (ja) 2022-09-14
JP2024010032A (ja) 2024-01-23

Similar Documents

Publication Publication Date Title
BR112022002122A2 (pt) Composição de mascaramento de sabor dispersível oralmente de hemibromidrato de vortioxetina, método para preparação da composição de mascaramento de sabor dispersível oralmente, e método para tratamento de um transtorno de depressão em um indivíduo
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
BR112018007560A2 (pt) composição cosmética tendo bactérias probióticas
WO2020086747A3 (en) Ssao inhibitors and uses thereof
MX2021016109A (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion.
BR112018008186A2 (pt) métodos que utilizam proteína de soro de leite para melhorar ou manter a qualidade muscular
BR112021016296A2 (pt) Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele
TR201908938T4 (tr) Ağız, boğaz ve solunum yolu rahatsızlıklarının tedavisi için formülasyonlar.
BR112019005985A2 (pt) composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico
EP3982994A4 (en) COMPOSITIONS AND METHODS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS
CR20210158A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
EP3968916A4 (en) GLAND TREATMENT DEVICES AND METHODS OF TREATING DRY EYE DISEASE
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
BR102020023578A8 (pt) Composições e métodos para tratamento do olho
BR112019000706A8 (pt) Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo
EP3897181A4 (en) ORAL EGG IMMUNOTHERAPY FORMULATIONS, MANUFACTURING METHODS AND TREATMENTS FOR EGG ALLERGIES
PL423673A1 (pl) Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis
EP3765062A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYGLUCOUS DISORDERS
EP3777849A4 (en) PHARMACEUTICAL COMPOSITION, COMPRISING POLMACOXIB AND PREGABALIN, FOR THE TREATMENT OF PAIN
HK1246639A1 (zh) 口服藥物組合物和其用於製備治療或預防疾病的藥物的用途
MX2019005818A (es) Preparacion cosmetica de viscosidad mejorada para tratamiento de fibras queratinicas, metodo para incrementar la viscosidad de una preparacion cosmetica, uso de ingredientes modificadores de la viscosidad y metodo de tratamiento de fibras queratinicas.

Legal Events

Date Code Title Description
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023014426-0 PROTOCOLO 870230063013 EM 18/07/2023 17:24.